Biotech entity
Every one of those 1 sits in a single category, pharma. Boston Scientific is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 3 original sources on average. We currently track 1 Biotech story that mention Nevro, all published on February 27, 2026.
Last mentioned: Feb 27, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Boston Scientific is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 3 original sources on average. We currently track 1 Biotech story that mention Nevro, all published on February 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Nevro. Shared-story counts are live from our verified record — not editorial picks.
The Australian government is significantly reducing subsidies for high-cost spinal cord stimulators following reports of severe patient injuries and a lack of clinical efficacy. This regulatory shift targets a multi-million dollar sector of the medical device market, forcing manufacturers to justify the high price tags of chronic pain technologies.
Nevro is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
